Key facts
- · Type: Amendment first sale 2026-03-24 · Amount sold: $2.16M · Total offering: $8M · SEC filing
- · Type: New offering first sale 2026-03-24 · Amount sold: $110K · Total offering: $8M · SEC filing
- · Type: Amendment first sale 2025-10-30 · Amount sold: $6.85M · Total offering: $23.50M · SEC filing
- · Type: Amendment first sale 2025-10-30 · Amount sold: $5.97M · Total offering: $23.50M · SEC filing
- · Type: Amendment first sale 2025-10-30 · Amount sold: $5.32M · Total offering: $23.50M · SEC filing
Is Alume Biosciences Inc a real, registered company?
Alume Biosciences Inc is a registered filer with the SEC (CIK 1782348) and has filed since 2023-01-09. 8 filings are on record, the latest on 2026-05-08.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Who runs Alume Biosciences Inc?
Alume Biosciences Inc's filings name Brett Berman, Dan Bradbury, James Schmidt and 5 more as its officers, directors or promoters.
How much has Alume Biosciences Inc raised?
Its new offerings report $15.93M sold across 3 offerings, as its own filings state.
Run the free check on Alume Biosciences Inc →
LA JOLLA, CALIFORNIA
Biotechnology
8
$15.93M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-05-08 | Amendment first sale 2026-03-24 | $2.16M | $8M | SEC filing |
| 2026-04-06 | New offering first sale 2026-03-24 | $110K | $8M | details · SEC filing |
| 2026-02-19 | Amendment first sale 2025-10-30 | $6.85M | $23.50M | SEC filing |
| 2026-01-30 | Amendment first sale 2025-10-30 | $5.97M | $23.50M | SEC filing |
| 2025-12-31 | Amendment first sale 2025-10-30 | $5.32M | $23.50M | SEC filing |
| 2025-11-12 | Amendment first sale 2025-10-30 | $3.61M | $23.50M | SEC filing |
| 2025-10-31 | New offering first sale 2025-10-30 | $3.06M | $23.50M | details · SEC filing |
| 2023-01-09 | New offering first sale 2022-12-28 | $12.76M | $45.02M | SEC filing |
Want the whole picture on Alume Biosciences Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Alume Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alume Biosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Alume Biosciences Inc's own filings with the SEC. The people those filings name are on the team page.